We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Benchling Raises $50M Series D To Accelerate Biotech Revolution
Product News

Benchling Raises $50M Series D To Accelerate Biotech Revolution

Benchling Raises $50M Series D To Accelerate Biotech Revolution
Product News

Benchling Raises $50M Series D To Accelerate Biotech Revolution


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Benchling Raises $50M Series D To Accelerate Biotech Revolution"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Benchling has announced it closed $50 million in Series D funding led by Alkeon and joined by new investors Spark Capital, Lux Capital and ICONIQ Partners, as well as existing investors Thrive Capital, Benchmark and Menlo Ventures. The round comes at one of the most pivotal moments for the biotechnology industry as companies race to deliver diagnostics, therapeutics and vaccines for COVID-19, while advances such as CRISPR and lab robotics continue to fuel breakthroughs in medicine, food and agriculture, energy and materials. Benchling will use the investment to build advanced product capabilities, expand its international presence, and drive adoption across leading R&D organizations, bringing the power of modern-day software to drive the rapid transformation of the life sciences industry.

"The disciplines of biopharma and biotech will create solutions that address some of our generation's biggest challenges, from COVID-19 and various forms of cancer to other serious threats to our welfare," said Mark McLaughlin, general partner at Alkeon. "Benchling has engineered an end-to-end, purpose-built software platform indispensable to life sciences companies leading the charge on global R&D. Scientists on the front lines of groundbreaking research leverage Benchling as go-to infrastructure that empowers them to innovate and collaborate at scale, while doing so with unprecedented speed and accuracy."

Since launching in 2012, more than 230,000 scientists and 1,000 R&D organizations have adopted Benchling's cloud platform to centralize massively complex experimental datasets and optimize R&D processes. Benchling doubled its customer base over the past year across industries ranging from pharmaceuticals and fuels to agriculture and food. Scientists report that the solution doubles R&D productivity, with customers at the forefront of COVID-19 research, such as Gilead Sciences, Regeneron Pharmaceuticals and Mammoth Biosciences, seeing usage soar 54% since the start of the pandemic.

Benchling is dedicated to supporting the historic effort to fight COVID-19. The company has launched several new initiatives to accelerate the COVID-19 response, including:

  • Offering the Benchling platform pro bono for COVID-19 testing and research. Quantitative Biosciences Institute at UCSF, UC Davis, Corteva Agriscience and more have adopted Benchling's platform to speed up testing and research.    
  • Providing a free, publicly accessible resource board for scientists, academics and governments to aggregate and exchange all available data on the virus, helping speed efforts to find a cure.
  • Centralizing donation requests from the scientific community for COVID-19 testing reagents, instruments and personal protective equipment (PPE).
Advertisement